NirvaMed

Executive Summary

NirvaMed Inc. is a pioneering medical device startup focused on developing advanced catheter-based treatments for ST-Elevation Myocardial Infarction (STEMI) and complex percutaneous coronary intervention (PCI). Founded in 2018, the company employs a dual-location strategy with operations in Minnesota, USA, and research in Thailand to leverage cost efficiencies and global talent. Its mission is to improve cardiac patient outcomes through innovative cooling and interventional technologies. While the company is private and early-stage, its focus on addressing high unmet needs in cardiac care positions it for potential growth if its technologies prove successful in clinical trials. The company operates in a competitive market, but its differentiated approach using cooling technology could offer advantages in reducing myocardial damage during heart attacks. Key risks include early-stage development, lack of disclosed funding, and regulatory hurdles. The company has not yet reported any products on the market, FDA approvals, or clinical publications. Success will depend on advancing its pipeline through preclinical and clinical studies, securing financing, and obtaining regulatory clearances. Investors should monitor progress in these areas.

Upcoming Catalysts (preview)

• Q4 2026FDA Breakthrough Device Designation50% success
• Q2 2027Completion of Pivotal Trial Enrollment30% success
• Q1 2027Series A Funding Round60% success